Oragenics, Inc. (OGEN)
NYSEAMERICAN: OGEN · Real-Time Price · USD
1.160
-0.010 (-0.85%)
Aug 12, 2025, 3:58 PM - Market open
Company Description
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States.
Its lead product is ONP-002 for the treatment of mild traumatic brain injury, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification.
The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and lantibiotics. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Sarasota, Florida.
Oragenics, Inc.
| Country | United States |
| Founded | 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Janet Huffman |
Contact Details
Address: 1990 Main Street, Suite 750 Sarasota, Florida 34236 United States | |
| Phone | 813 286 7900 |
| Website | oragenics.com |
Stock Details
| Ticker Symbol | OGEN |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001174940 |
| CUSIP Number | 684023609 |
| ISIN Number | US6840236094 |
| Employer ID | 59-3410522 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Janet Huffman | Chief Executive Officer, President, Chief Financial Officer, Secretary and Treasurer |
| Charles L. Pope CPA | Executive Chairman |
| Greg Gironda | Head of Business Development |
| Dr. James P. Kelly M.A., M.D. | Chief Medical Officer |
| Dr. William Franklin Peacock IV, F.A.C.E.P., FACC, M.D. | Chief Clinical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 11, 2025 | 8-K | Current Report |
| Aug 8, 2025 | 10-Q | Quarterly Report |
| Jul 2, 2025 | 8-K | Current Report |
| Jul 2, 2025 | SCHEDULE 13G | Filing |
| Jul 2, 2025 | 424B5 | Filing |
| Jun 30, 2025 | EFFECT | Notice of Effectiveness |
| Jun 30, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jun 23, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 13, 2025 | 144 | Filing |
| Jun 3, 2025 | DRS | [Cover] Draft Registration Statement |